GTB-3650 Tri-Specific Killer Engager (TriKE®)
HM2023-05: GTB-3650 (Anti-CD16/IL-15/Anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)
Arms / Cohorts
Experimental, Arm 1:Dose Level 1: 1.25 ug/kg/day
Accepting patients
Experimental, Arm 2:Dose Level 2: 2.5 ug/kg/day
Accepting patients
Experimental, Arm 3:Dose Level 3: 5 ug/kg/day
Accepting patients
Experimental, Arm 4:Dose Level 4: 10 ug/kg/day
Accepting patients
Experimental, Arm 5:Dose Level 5: 25 ug/kg/day
Accepting patients
Experimental, Arm 6:Dose Level 6: 50 ug/kg/day
Accepting patients
Experimental, Arm 7:Dose Level 7: 100 ug/kg/day
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.